| http://www.w3.org/ns/prov#value | - St??phane Thiroloix, Ipsen???s Executive Vice-President, Corporate Development added: ???Despite the discontinuation of BIM 23A760 development, Ipsen remains fully committed to bringing value-added therapies to patients and clinicians in endocrinology, especially in the treatment of statural and pituitary disorders.
|
